Fondation pour la Recherche Médicale

The Fondation pour la Recherche Médicale, commonly known as the FRM, is a French charitable foundation dedicated to supporting public research across medicine and pathophysiology. It was created in 1947 as the Association pour la recherche médicale by researchers and physicians including Jean Bernard and Jean Hamburger. Unlike organizations focused on one disease, the foundation developed a broad remit covering the major areas of human health, including cancer, Alzheimer's disease, cardiovascular disease, leukemia, diabetes, multiple sclerosis, Parkinson's disease, age-related diseases, infectious diseases and rare diseases. The organization progressively moved from an association-based structure toward foundation status. It acquired foundation status in 1962 after a national appeal for private support signed by 132 researchers and doctors, and it was recognized as being of public utility on 14 May 1965. This recognition reinforced its role as a national philanthropic institution supporting research in the public interest while remaining financially independent of direct state funding. The FRM's operating model is based primarily on donations, legacies and partner contributions. It presents itself as a donor-funded organization rather than a state-financed research agency. Donors may request that their contributions support a particular research field, subject to the foundation's procedures. The foundation participates in the French Charter Committee framework intended to promote confidence in charitable fundraising, and its financial activity is reviewed by an independent auditor. Certified accounts and activity reports are made publicly available through its communications channels. Research funding is allocated through calls for projects and scientific assessment. The Scientific Council reviews applications and submits its recommendations to the governing bodies for approval. The council consists of researchers working in public or mixed research institutions. The foundation's supervisory board determines strategic priorities, while a management board and a small professional staff handle scientific affairs, development and communications, and administration and finance. The governing and scientific bodies are described as voluntary, although the foundation employs staff for its operating activities. FRM-backed research has been associated with several reported advances. These include the identification of a gene involved in blood-pressure regulation in 1983, the identification during 1990–1991 of the genetic abnormality associated with acute promyelocytic leukemia, evidence in 2000 for deep-brain stimulation in severe Parkinson's disease, and work reported in 2014 on the use of stem cells to improve cardiac function after myocardial infarction. These examples illustrate the foundation's cross-disease approach and its support for both fundamental and translational research. Public awareness and fundraising are important parts of the FRM brand. Since the 1990s, public figures including Thierry Lhermitte, Clotilde Courau, Marina Carrère d'Encausse, Nagui and Marc Lévy have supported its communications or fundraising efforts. The foundation also conducts an annual national mobilization in September focused on Alzheimer's disease, with ambassadors and media personalities calling attention to research needs and donations. The FRM therefore combines grant-making, donor stewardship, scientific communication and public campaigns within a single nonprofit identity. The foundation remains active in France and continues to position itself as an independent, generalist medical-research funder. In 2022, it dedicated €47 million to medical research and supported more than 400 research projects, according to the cited reference material. Its public-interest recognition, scientific review process, donor-funded model and emphasis on transparency form the central elements of its institutional positioning.

The Fondation pour la Recherche Médicale traces its origins to 1947, when the Association pour la recherche médicale was established by researchers and physicians including Jean Bernard and Jean Hamburger. From the beginning, its mission was deliberately broad: rather than concentrating on one illness, it sought to support research across medicine and pathophysiology. This remit allowed the organization to address changing health priorities and to fund work spanning cancers, neurodegenerative conditions, cardiovascular disease, diabetes, blood disorders, infectious diseases, rare diseases and diseases associated with aging. A major institutional transition occurred in 1962, when the association acquired foundation status following a private-aid appeal signed by 132 researchers and doctors. On 14 May 1965, it was recognized as being of public utility. That status established the FRM as a public-interest philanthropic institution while leaving it reliant on private generosity rather than direct state funding. Donations, legacies and partner contributions became the financial basis for its research-support activities. The foundation's grant-making model developed around scientific evaluation. Research teams submit proposals through calls for projects, and the Scientific Council examines the applications before transmitting its recommendations to the governing board. The council is composed of researchers active in public or mixed institutions, providing a link between the foundation's philanthropic resources and the French public research community. Strategic direction is set by the supervisory board, supported by management functions covering scientific affairs, development and communications, and administration and finance. Research supported by the FRM has been connected with a number of reported advances. In 1983, work supported by the foundation contributed to identifying a key gene involved in blood-pressure regulation. During 1990 and 1991, research addressed the genetic abnormality responsible for acute promyelocytic leukemia. In 2000, evidence emerged concerning the effectiveness of deep-brain stimulation for severe forms of Parkinson's disease. In 2014, supported work examined the use of stem cells to improve cardiac function after myocardial infarction. These examples reflect the institution's interest in both fundamental mechanisms and potential clinical applications. The FRM also expanded its public-facing identity through communication and fundraising. From the 1990s onward, actors, physicians, presenters, authors and other public figures helped promote its appeals. Named supporters have included Thierry Lhermitte, Clotilde Courau, Marina Carrère d'Encausse, Nagui and Marc Lévy. The foundation's recurring September Alzheimer's campaign became one of its visible national mobilization activities, using ambassadors such as M Pokora, Laury Thilleman, Élie Semoun and Tom Villa to encourage public attention and donations. Accountability is a central part of the foundation's operating model. It participates in the Charter Committee framework associated with trustworthy charitable fundraising, has its expenditure reviewed by an independent auditor, and publishes certified accounts and activity reports. Donors may ask for their gifts to be directed toward a particular research area. The FRM has also stated that it does not receive state funds, emphasizing its independence and its reliance on civil-society support. In the governance period documented by the reference material, Pierre Joly chaired the supervisory board from 1983 to 2010, Jacques Bouriez from 2010 to 2017, and Denis Duverne from September 2017 onward. The foundation was reported to employ 42 people for operational work, while its governance and scientific bodies were voluntary. In 2022, it dedicated €47 million to medical research and supported more than 400 research projects. The FRM consequently combines national fundraising, transparent charitable administration and broad-based medical-research financing under a single French nonprofit brand.

• 2022

  Funding of more than 400 research projects

  [1]Fondation pour la recherche médicaleen.wikipedia.org

  The foundation reported dedicating €47 million to medical research and supporting more than 400 projects.

• 2014

  Stem-cell research after myocardial infarction

  [1]Fondation pour la recherche médicaleen.wikipedia.org

  Supported research examined the use of stem cells to improve cardiac function after myocardial infarction.

• 2000

  Deep-brain stimulation research

  [1]Fondation pour la recherche médicaleen.wikipedia.org

  Supported work provided evidence for the effectiveness of deep-brain stimulation in severe Parkinson's disease.

• 1990

  Research on acute promyelocytic leukemia

  [1]Fondation pour la recherche médicaleen.wikipedia.org

  Research during 1990–1991 identified the genetic abnormality associated with acute promyelocytic leukemia.

• 1983

  Blood-pressure regulation research

  [1]Fondation pour la recherche médicaleen.wikipedia.org

  Supported research identified a key gene involved in the regulation of blood pressure.

• 1965

  Recognition as a public-interest foundation

  [1]Fondation pour la recherche médicaleen.wikipedia.org

  The organization was recognized as being of public utility on 14 May 1965.

• 1962

  Acquisition of foundation status

  [1]Fondation pour la recherche médicaleen.wikipedia.org

  The association acquired foundation status after a private-support appeal signed by 132 researchers and doctors.

• 1947

  Creation of the Association pour la recherche médicale

  [1]Fondation pour la recherche médicaleen.wikipedia.org

  The organization that became the Fondation pour la Recherche Médicale was created by researchers and physicians including Jean Bernard and Jean Hamburger.

An independent French public-interest medical-research foundation funded by private generosity and distinguished by a broad, cross-disease approach, scientific peer review and donor-transparency practices.

• Research funding · 1947

  Medical research grants

  The FRM finances research projects across medicine and pathophysiology rather than restricting support to a single disease. Applications are assessed through calls for projects and reviewed by the foundation's Scientific Council before approval by the governing bodies. Supported fields include cancer, neurological disease, cardiovascular conditions, diabetes, blood disorders, infectious disease, rare disease and age-related illness.

• Philanthropic services · 1947

  Donation and legacy programs

  Donations and legacies are the foundation's principal source of funding. Donors can request that their contributions support a specific area of research, while the organization communicates its public-interest status, independent auditing and publication of certified accounts to support donor confidence.

• Public-awareness campaign

  Alzheimer's disease mobilization

  The foundation's recurring September national mobilization raises public awareness and donations for Alzheimer's disease research. The campaign uses public ambassadors and media communication to connect the FRM's general medical-research mission with a high-profile disease-specific appeal.

• National Alzheimer's disease mobilization

  France

  Each September, the FRM conducts a national fundraising and awareness campaign focused on Alzheimer's disease research. Public ambassadors, including M Pokora, Laury Thilleman, Élie Semoun and Tom Villa, have been cited as participants in appeals for donations.

  Outcome. The campaign serves as a recurring national fundraising and public-engagement program; a specific campaign total is not provided in the reference material.

  Source

1. 1Fondation pour la recherche médicaleen.wikipedia.org
2. 2Fondation pour la Recherche Médicale official websitefrm.org